Marlene Garzarolli

567 total citations
20 papers, 220 citations indexed

About

Marlene Garzarolli is a scholar working on Molecular Biology, Oncology and Dermatology. According to data from OpenAlex, Marlene Garzarolli has authored 20 papers receiving a total of 220 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Oncology and 5 papers in Dermatology. Recurrent topics in Marlene Garzarolli's work include Melanoma and MAPK Pathways (7 papers), CAR-T cell therapy research (5 papers) and Brain Metastases and Treatment (4 papers). Marlene Garzarolli is often cited by papers focused on Melanoma and MAPK Pathways (7 papers), CAR-T cell therapy research (5 papers) and Brain Metastases and Treatment (4 papers). Marlene Garzarolli collaborates with scholars based in Germany, United States and Greece. Marlene Garzarolli's co-authors include Friedegund Meier, Ricarda Rauschenberg, Annette Stein, Irene Schmidtmann, Ralph Muecke, Dorothée Nashan, Karsten Muenstedt, Christoph Stoll, Jutta Huebner and Oliver Micke and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Marlene Garzarolli

19 papers receiving 217 citations

Peers

Countries citing papers authored by Marlene Garzarolli

Since Specialization

Citations

This map shows the geographic impact of Marlene Garzarolli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marlene Garzarolli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marlene Garzarolli more than expected).

Fields of papers citing papers by Marlene Garzarolli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marlene Garzarolli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marlene Garzarolli. The network helps show where Marlene Garzarolli may publish in the future.

Co-authorship network of co-authors of Marlene Garzarolli

This figure shows the co-authorship network connecting the top 25 collaborators of Marlene Garzarolli. A scholar is included among the top collaborators of Marlene Garzarolli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marlene Garzarolli. Marlene Garzarolli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA45 Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trial 2024 ·Annals of Oncology ·(unknown), (unknown), Lidija Kandolf Sekulović, Friedegund Meier, Thomas Eigentler, Mirjana Ziemer, (unknown), Anja Gesierich, Rudolf Herbst, Katharina C. Kähler, Dimitrios C. Ziogas, Željko Mijušković, Marlene Garzarolli, Christine Garbe, Alexander Roesch, (unknown), (unknown), (unknown), (unknown), (unknown)	1
2	Raising awareness of immune-related side effects in oncological patients under palliative care: a report of two cases 2023 ·Annals of Palliative Medicine ·(unknown), (unknown), Mirjana Ziemer, Martin Neukirchen, Jacqueline Schwartz, Michael Sachse, Marlene Garzarolli, (unknown), Lydia Reinhardt, Martin Kaatz, Ulrich S. Schuler, Friedegund Meier	1
3	Lower leg reconstruction after resection of a squamous cell carcinoma on necrobiosis lipoidica with a pedicled fibula and an extended anterolateral thigh flap—a case report 2023 ·World Journal of Surgical Oncology ·(unknown), Friedegund Meier, Marlene Garzarolli, Klaus‐Dieter Schaser, Adrian Dragu, (unknown), (unknown)	2
4	Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAF^V600-positive melanoma: Interim analysis of the ImmunoCobiVem study. 2022 ·Journal of Clinical Oncology ·Dirk Schadendorf, Helen Gogas, Lidija Kandolf Sekulović, Friedegund Meier, Thomas Eigentler, Jan‐Christoph Simon, Patrick Terheyden, Anja Gesierich, Rudolf Herbst, Katharina C. Kähler, Dimitrios C. Ziogas, Željko Mijušković, Marlene Garzarolli, Claus Garbe, Alexander Roesch, Selma Ugurel, Ralf Gutzmer, Jean‐Jacques Grob, Lisa Zimmer, Elisabeth Livingstone	6
5	An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study 2020 ·Neuro-Oncology Advances ·Teresa Amaral, Heike Niessner, Tobias Sinnberg, Ioannis Thomas, (unknown), Claus Garbe, Marlene Garzarolli, Ricarda Rauschenberg, Thomas Eigentler, Friedegund Meier	11
6	Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations—Chances and Challenges 2018 ·American Journal of Clinical Dermatology ·M. Kuske, Ricarda Rauschenberg, Marlene Garzarolli, (unknown), Stefan Beissert, Esther G.C. Troost, (unknown), Friedegund Meier	9
7	Informationssuche und Nutzung von Informationsquellen durch Melanompatienten deutscher Hautkrebszentren 2018 ·JDDG Journal der Deutschen Dermatologischen Gesellschaft ·(unknown), (unknown), Marlene Garzarolli, Ricarda Rauschenberg, Christiane Weber, Carola Berking, Wolfgang Tilgen, Dirk Schadendorf, Friedegund Meier, (unknown)	3
8	Unmet information needs of patients with melanoma in Germany 2018 ·Melanoma Research ·(unknown), (unknown), Marlene Garzarolli, Ricarda Rauschenberg, Christiane Weber, Carola Berking, Wolfgang Tilgen, Dirk Schadendorf, Friedegund Meier	13
9	Information‐seeking and use of information resources among melanoma patients of German skin cancer centers 2018 ·JDDG Journal der Deutschen Dermatologischen Gesellschaft ·(unknown), (unknown), Marlene Garzarolli, Ricarda Rauschenberg, Christiane Weber, Carola Berking, Wolfgang Tilgen, Dirk Schadendorf, Friedegund Meier, (unknown)	14
10	Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia 2018 ·Blood Advances ·Anne Sophie Kubasch, Rebekka Wehner, (unknown), Antje Tunger, Sebastian Stasik, Marlene Garzarolli, Jörn Meinel, Gustavo Baretton, Friedegund Meier, Christian Thiede, Marc Schmitz, Uwe Platzbecker	5
11	Interactions from complementary and alternative medicine in patients with melanoma 2017 ·Melanoma Research ·Carmen Loquai, Irene Schmidtmann, Marlene Garzarolli, Martin Kaatz, Katharina C. Kähler, Peter Kurschat, Frank Meiß, Oliver Micke, Ralph Muecke, Karsten Muenstedt, Dorothée Nashan, Annette Stein, Christoph Stoll, (unknown), Jutta Huebner	19
12	An open-label, uncontrolled, single arm phase II trial of the PI3K inhibitor buparlisib in patients with melanoma brain metastases. 2017 ·Journal of Clinical Oncology ·Friedegund Meier, Andrea Forschner, Marlene Garzarolli, Ricarda Rauschenberg, Stefan Beissert, Claus Garbe, Thomas Eigentler	2
13	An unusual case of Cowden syndrome associated with ganglioneuromatous polyposis 2016 ·Hereditary Cancer in Clinical Practice ·Steffen Pistorius, Barbara Klink, Jessica Pablik, Andreas Rump, Daniela E. Aust, Marlene Garzarolli, Evelin Schröck, Hans K. Schackert	6
14	Hirnmetastasen des malignen Melanoms 2016 ·Der Hautarzt ·Ricarda Rauschenberg, Ghazaleh Tabatabai, Esther G.C. Troost, Marlene Garzarolli, Stefan Beissert, Friedegund Meier	3
15	Use of complementary and alternative medicine: A multicenter cross-sectional study in 1089 melanoma patients 2016 ·European Journal of Cancer ·Carmen Loquai, (unknown), Marlene Garzarolli, Martin Kaatz, Katharina C. Kaehler, Peter Kurschat, Frank Meiß, Oliver Micke, Ralph Muecke, Karsten Muenstedt, Annette Stein, Dorothée Nashan, Christoph Stoll, Irene Schmidtmann, Jutta Huebner	51
16	Risk of interactions between complementary and alternative medicine and medication for comorbidities in patients with melanoma 2016 ·Medical Oncology ·Carmen Loquai, (unknown), Marlene Garzarolli, Martin Kaatz, Katharina C. Kaehler, Peter Kurschat, Frank Meiß, Annette Stein, Dorothée Nashan, Oliver Micke, Ralph Muecke, Karsten Muenstedt, Christoph Stoll, Irene Schmidtmann, Jutta Huebner	28
17	Systemtherapie des metastasierten malignen Melanoms 2015 ·JDDG Journal der Deutschen Dermatologischen Gesellschaft ·Ricarda Rauschenberg, Marlene Garzarolli, Ursula M. Dietrich, Stefan Beissert, Friedegund Meier	2
18	Systemic therapy of metastatic melanoma 2015 ·JDDG Journal der Deutschen Dermatologischen Gesellschaft ·Ricarda Rauschenberg, Marlene Garzarolli, Ursula M. Dietrich, Stefan Beissert, Friedegund Meier	20
19	Effectiveness of Interdisciplinary vs. Dermatological Care of Moderate- to-severe Psoriasis: A Pragmatic Randomised Controlled Trial 2014 ·Acta Dermato Venereologica ·Jochen Schmitt, Gottfried Wozel, Marlene Garzarolli, (unknown), Michael Bauer, Karolina Leopold	18
20	Sun Protection Training Based on a Theater Play for Preschoolers: an Effective Method for Imparting Knowledge on Sun Protection? 2013 ·Journal of Cancer Education ·(unknown), (unknown), Marlene Garzarolli, Sandra M. Herrmann, Eckhard W. Breitbart, Hendrik Berth, Michaël Baumann, Gerhard Ehninger	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact